Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Lilly linked the molecule to a 50% reduction of tau ... In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering ...

Management also reiterated its plans to file an investigational new drug (IND) application with the FDA before the end of this year to advance an internally developed amylin agonist program to ...

VK2809 is an orally available small molecule agonist of the thyroid ... we announced data from a new program targeting novel agonists of the amylin receptor for the potential treatment of obesity.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Terns' pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

During the year, the company also announced a new pipeline program focused on novel internally developed dual agonists of the amylin and calcitonin receptors. In preclinical models, these ...

Dual Amylin and Calcitonin Receptor Agonist (DACRA ... Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment ...

In rats, studies with dual amylin and calcitonin receptor agonists have demonstrated robust body weight loss, improved glucose tolerance and a decreased deposition of fat in liver tissue beyond what ...